Editorial – Managing Risk in Uncertain Times

2021 ◽  
Vol 20 (1) ◽  
pp. 2-3
Author(s):  
Ben Lovell ◽  

In February 2021 Jon Hilton (AIM ST4 doctor) published a tweet asking about how the Acute Medicine community can best address potential applicant’s fears of dealing with clinical risk. ​(1)​ Appraising and managing risk is at the core of acute medical clinical practice; we treat patients in the first crucial 24 hours of their hospital journey, when the clinical status is changeable, and the clinical trajectory not yet established. We make judgement calls about medical treatment, but also about whether a patient can be safely discharged home, and this often causes anxiety amongst less experienced clinicians: how do you make that call? Dealing with risk can be tricky to teach. It is a skill that stands on two legs: one leg is data and the other is clinical experience. As the pandemic intensified, Acute Medicine’s role as front door risk managers became more important than ever before. We displayed massive amounts of creativity and initiative to develop pathways and processes to ensure patients were followed up at home. But we were still operating with many unknown variables and did not yet have the experience nor the data required to make the crucial risk calculations and judgement calls that forms the heart of our working practice. Long before we began to recognise patterns in our patients in their diseases, and before we began to create a new language to describe and communicate what we were seeing – the ‘happy hypoxic’ and the ‘day-10 wobble’ – we operated in a form of darkness, making the best decisions we could. One year and two COVID-19 peaks later, we are better able to make nuanced decisions about patient risk, and reach collaborative plans with our patients, as the international COVD-19 academic library grows and elaborates. In this issue Azijli et al ​(2)​ present the findings of the COVERED trial, which establishes a validated model that predicts poor outcomes in patients in the Emergency Department. This model is a tool that can help power our risk perception and clinical decision-making on the medical take. Deciding whether to thrombolyse an acute pulmonary embolism is another exercise in risk management. Weighing the risk of death from obstructive shock against death from haemorrhage, whilst remaining mindful of the longterm cardiopulmonary sequel of an untreated high-risk PE. Apsey et al ​(3)​ followed up patients with massive and sub-massive emboli who received emergency thrombolytic therapy and favour an acute thrombolysis strategy in their conclusion. This is a small study, but provides some substrate for reflection: how do we perceive the risks of thrombolysis in out own institutions, and how does the effect our patient care? It is not uncommon for physicians to be given a troponin results that they did not want nor request, but must now square away with their assessment and evaluation of a patient. Most of us shrink away from the descriptor ‘troponin-positive chest pain’ as a not-quite diagnosis, but when we have ruled out acute myocardial infarction, what conditions remain under this umbrella term? Hansen et al ​(4)​ describe the common conditions that lead to elevated troponin levels, and – crucially – tell us about these patients’ outcomes. Their paper shows us that patients with a high troponin, without an acute MI, have a very high mortality. This brings us back to risk: how do we keep these patients safe? The pandemic has brought dramatic changes into our clinical and personal lives. Our trainee doctors have undergone rapid redeployments to new work environments. They often moved from low-risk to high-risk COVID-19 environments with very little notice. Some of them became very sick with COVID-19. They have had expensive and mandatory examinations cancelled. Many have been left with uncertain futures, not knowing if they will be able to progress with their training programmes as anticipated. Aziminia et al ​(5)​ have captured their voice in this issue, and make suggestions toward helping trainees navigate this incredibly uncertain period in their medical careers.

2016 ◽  
Vol 2 (2) ◽  
Author(s):  
Carlo Bova ◽  
Vitaliano Spagnuolo ◽  
Alfonso Noto

Pulmonary embolism (PE) is a common disease with a not negligible short-term risk of death, in particular in the elderly. An adequate evaluation of the prognosis in patients with PE may guide decision-making in terms of the intensity of the initial treatment during the acute phase. Patients with shock or persistent hypotension are at high risk of early mortality and may benefit from immediate reperfusion. Several tools are available to define the short-term prognosis of hemodynamically stable patients. The pulmonary embolism severity index (PESI) score, and the simplified PESI score are particularly useful for identifying patients at low risk of early complications who might be safely treated at home. The identification of patients who are hemodynamically stable at diagnosis but are at a high risk of early complications is more challenging. Current guidelines recommend a multi-parametric prognostic algorithm based on the clinical status, biomarkers and imaging tests. However an aggressive treatment in hemodynamically stable patients is still controversial.


2009 ◽  
Vol 15 (3) ◽  
pp. 192-198 ◽  
Author(s):  
Andrew Carroll

SummaryMaking decisions in the context of risk is an integral part of psychiatric work. Despite this, decision-making skills are rarely systematically taught and the processes behind decisions are rarely made explicit. This article attempts to apply contemporary evidence from cognitive and social psychology to common dilemmas faced by psychiatrists when assessing and managing risk. It argues that clinical decision-making should acknowledge both the value and limitations of intuitive approaches in dealing with complex dilemmas. After discussing the various ways in which clinical decision-making is commonly derailed, the article outlines a framework that accommodates both rational and intuitive modes of thinking, with the aim of optimising decision-making in high-risk situations.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 9636-9636 ◽  
Author(s):  
Sara R. Alcorn ◽  
Thomas J. Smith ◽  
Todd R. McNutt ◽  
M. Jennifer Cheng ◽  
Sydney Morss Dy ◽  
...  

9636 Background: The care of patients who receive radiation therapy (RT) at the end of life (EOL) is under scrutiny to ensure effectiveness and value, with many patients not completing RT (Gripp, 2010; Toole, 2012). This retrospective analysis seeks to describe patterns of utilization of palliative RT, including rates of completion of RT offered at the EOL and the use of single fraction RT for bone metastases. Methods: Electronic medical records were used to create a database of 3,383 RT plans for brain, bone, lung, and other metastatic sites in patients treated at Johns Hopkins Hospital from 9/1/2007-7/15/2012. RT plans without palliative intent were excluded. T-tests and logistic regression compared patient and treatment characteristics between patients who died > 1 month versus ≤ 1 month after their last RT fraction. Results: A total of 983 patients were treated to 1,524 sites, with an average of 1.7 RT sites (SD 1.3) per patient. Of these, 872 (89%) patients had complete records and were included in analysis. At the time of analysis, 85% had died. The mean age of 62.1 years (SD 3.4) did not differ statistically based on time from RT to death. Death ≤ 1 month after RT was documented in 215 (24.7%) patients. Compared to patients living > 1 month after RT, patients receiving RT within the last month of life were more likely to be lung (17% versus 9%), less likely to be brain (34% versus 44%), and equally likely to be bone (45% versus 43%) sites. Patients who died ≤ 1 month after completing RT spent on average 5 days (16.6%) of the last month of life receiving RT, with no significant difference by disease site. Conclusions: Most patients receiving palliative RT finish therapy, with 25% dying ≤ 1 month after RT. Single fraction bone RT was relatively uncommon, with no significant difference in the rates of single fraction RT based on time from RT to death. These data provide a framework to match treatment patterns with national guidelines. Additionally, they provide context to model risk of death shortly after RT, which can aid in clinical decision-making. [Table: see text]


2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 167-167
Author(s):  
Edoardo Francini ◽  
Fang-Shu Ou ◽  
Stefano Lazzi ◽  
Roberto Petrioli ◽  
Andrea Giovanni Multari ◽  
...  

167 Background: Previous studies have reported high TILs are a favorable prognostic factor in stage II CC. However, whether the impact of TILs on overall survival (OS) differs among pts who did or did not receive ADJ is still to be determined. We assessed the prognostic value of CD3+ TILs in pts with stage II CC according to whether they received ADJ or not (no-ADJ). Methods: Pts treated with curative surgery for stage II CC (2002-2013) were identified through the Santa Maria alle Scotte Hospital database. CD3+ TILs at the invasive front, center of tumor, and stroma, were determined by immunohistochemistry and manually quantified as the rate of TILs/total tissue areas. High TILs (H-TILs) was defined as > 20%. Pts were classified as high or low TILs (L-TILs) and ADJ or no-ADJ. Cox models were used to assess OS with hazard ratio estimates (95% CI). Results: Of the 678 pts included (356 deaths), 137 (20%) received ADJ while 541 (80%) did not. ADJ comprised fluoropyrimidine +/- oxaliplatin. Median follow-up was 8.5 years. The distributions of the 4 groups were: 16% (L-TIL/ADJ), 64% (L-TIL/no-ADJ), 5% (H-TIL/ADJ), 15% (H-TIL/no-ADJ). Compared to H-TILs/no-ADJ, ADJ pts had a significantly longer OS (P < .0001) regardless of the TILS rate while L-TILs/no ADJ had significantly shorter OS and higher risk of death (HR = 1.41; 95% CI, 1.06-1.88; P < .0001) [See table]. On multivariable analysis, adjusting for perforation, obstruction, T-stage, grade, < 12 lymph nodes resected, lymphovascular and perineural invasion, the adverse prognostic impact of L-TILs (vs H-TILs) in no-ADJ pts was confirmed (HR = 1.36; 95% CI 1.02, 1.82; P = .0373). Conclusions: Low CD3+ TILs rate was independently associated with shorter OS in stage II CC pts who did not receive ADJ, but was not prognostic among pts who had ADJ. These data suggest a potentially different impact of TILs in chemo-treated vs -untreated stage II CC which could affect clinical decision making. [Table: see text]


2020 ◽  
Vol 84 (1) ◽  
pp. 3-20 ◽  
Author(s):  
Angela Lewis ◽  
Caroline Stokes ◽  
Isobel Heyman ◽  
Cynthia Turner ◽  
Georgina Krebs

It is not uncommon for patients with obsessive-compulsive disorder (OCD) to present with symptoms that suggest possible risk. This can include apparent risk, which reflects the content of obsessional fears, and genuine risk arising as the unintended consequence of compulsive behaviors. In both situations, risk can cause confusion in relation to diagnosis and treatment. The current article adds to the small existing literature on risk in OCD by presenting case examples illustrating different types of risk in the context of pediatric OCD, along with a discussion of their implications for management. The cases highlight that it is crucial that risk in OCD is considered carefully within the context of the phenomenology of the disorder. Guidance is offered to support clinical decision making and treatment planning.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2889-2889 ◽  
Author(s):  
Ella Willenbacher ◽  
Sofia Gasser ◽  
Günther Gastl ◽  
Wolfgang Willenbacher

Abstract Abstract 2889 Poster Board II-865 Introduction: Serum free light chain analysis (sFLCA) is a tool to monitor myeloma disease activity and treatment response, and stratify myeloma pts. to defined risk groups and has been incorporated into diagnostic guidelines[1]. Either the ratio of the free kappa/lambda light chains (FLCQ), the absolute value of the involved light chain (FLCi) or the difference of involved and uninvolved light chain (FLCD) may be used. While sFLCA is recommended , urine analysis (uFLCA) at the moment is not. To analyze whether results from sFLCA and uFLCA would potentially have translated into altered clinical decision making and timing of treatments compared to classical paraprotein measurements (sPPM) in a cohort of myeloma patients we analyzed all measurements routinely performed at Innsbruck University Hospital between MAR 03 and OKT 08 and correlated them to individual pts. clinical courses. Methods: 187 pts. (109 m, 78 f) out 235 pts. identified were deemed eligible. Myeloma subtypes were IgG (57.2%), IgA (21,9%), light chain only (13.9%), IgM (3.2%), oligo and nonsecretory (2.6 %, incl. 2 pts. completely asecretory), and IgD (1,0%). 4 pts. were complete immunoglobulin only secreters. According to mSMART 15% were high risk, 61% standard risk and 23,5% of unknown category. In this cohort 3202 sFLCa, 1136 uFLCa and 2583 sPPM were performed (range 2-89, median 12). This measurements were correlated with 167 treatment lines applied in this pts. (49 auto-transplants, 3 allo-transplants, 7 auto/allo procedures, 68 regimes containing novel agents and 40 conventional chemotherapeutic approaches. Patients, Assays and Treatment Lines: 187 pts. (109 m, 78 f) out 235 pts. identified were deemed eligible. Myeloma subtypes were IgG (57.2%), IgA (21,9%), light chain only (13.9%), IgM (3.2%), oligo and nonsecretory (2.6 %, incl. 2 pts. completely asecretory), and IgD (1,0%). 4 pts. were complete immunoglobulin only secreters. According to mSMART 15% were high risk, 61% standard risk and 23,5% of unknown category. In this cohort 3202 sFLCa, 1136 uFLCa and 2583 sPPM were performed (range 2-89, median 12). This measurements were correlated with 167 treatment lines applied in this pts. (49 auto-transplants, 3 allo-transplants, 7 auto/allo procedures, 68 regimes containing novel agents and 40 conventional chemotherapeutic approaches. Results: sFLCa showed a significant advantage in detecting any of the predefined clinical endpoints (Table 1) . By using sPPM only , ∼ 40% of events would have been missed during the observation period. A median of 13% of the applied therapies proven to be ineffective could have been stopped and altered earlier on using the results of sFLCa. While the use of sFLCi and sFLCD resulted in comparable rates of false pos. and neg. results (Table 2) in comparison to sPPM, sFLCQ is more sensitive to effects of immunoparesis, changes of the uninvolved FLC concentration and renal function resulting in both more false pos., as well as false neg. results. sFLCa detected relapses with a median of 3 months prior to sPPM, therapeutic effectiveness with a median of 2 therapy cycles earlier than sPPM and therapeutic failure with a median of 1 antecedent cycle of therapy. Data on uFLCa will be provided at ASH. Discussion: This analysis proves sFLCa to be a useful tool in monitoring myeloma pts. clinical courses and the therapeutic effectiveness of myeloma treatment approaches, even in the setting of “real life medicine”. For monitoring purposes sFLCi and sFLCD should be used preferably due the higher false pos./neg. potential of sFLCQ . By using sFLCa in a structured diagnostic pathway treatment effectiveness could be judged earlier on and altered if necessary. Thus this analysis shows a potentially clinically significant benefit to myeloma pts. [1] Dispenzieri et al. Leukemia advance online publication 20 November 2008; doi:10.1038/leu.2008.307 Disclosures: No relevant conflicts of interest to declare.


1999 ◽  
Vol 84 (1) ◽  
pp. 114-116 ◽  
Author(s):  
DeAnna L. Mori ◽  
Wayne Klein ◽  
Patricia Gallagher

Psychosocial factors are presented which affect clinical decision-making regarding the allocation of renal organs. Patients were rated as being either High Risk or Low Risk transplant candidates High Risk candidates were scored as being significantly different from the Low Risk candidates on many psychosocial variables. Interestingly, significant differences were not found between these two groups on either the MMPI–2 or the Beck Depression Inventory. The validity of using information from these inventories to allocate organs is discussed.


Sign in / Sign up

Export Citation Format

Share Document